by Physician’s Briefing Staff After approving Casgevy (exagamglogene autotemcel) in December to treat sickle cell disease, the U.S. Food and Drug Administration announced Tuesday that the therapy has now been approved to treat patients older than 12 years with transfusion-dependent beta-thalassemia. Casgevy is the first CRISPR-based medicine, where gene editing is used to develop the...
